|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Revenues from proprietary products | |||||
| Revenues from distribution | |||||
| Proprietary Products | |||||
| Distribution | |||||
| Total revenues | |||||
| Cost of revenues | |||||
| Cost of revenues from proprietary products | |||||
| Cost of revenues from distribution | |||||
| Proprietary Products | |||||
| Distribution | |||||
| Total cost of revenues | |||||
| Gross profit | |||||
| Research and development expenses | |||||
| Selling and marketing expenses | |||||
| General and administrative expenses | |||||
| Other expense | |||||
| Operating income | |||||
| Financial income | |||||
| Income (expenses) in respect of currency exchange differences and derivatives instruments, net | |||||
| Revaluation of long-term liabilities | |||||
| Financial expense | |||||
| Income before tax on income | |||||
| Taxes on income | |||||
| Net Income (Loss) | |||||
| Other Comprehensive Income: | |||||
| Gain (loss) on cash flow hedges | |||||
| Net amounts transferred to the statement of profit or loss for cash flow hedges | |||||
| Items that will not be reclassified to profit or loss in subsequent periods: | |||||
| Remeasurement gain (loss) from defined benefit plan, net of tax | |||||
| Tax effect | |||||
| Total comprehensive income (loss) | |||||
| Total comprehensive income | |||||
| Earnings per share attributable to equity holders of the Company: | |||||
| Basic net earnings per share (in Dollars per share) | |||||
| Diluted net earnings per share (in Dollars per share) |
Loading...